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Peroxynitrite is a potent oxidant that is quickly emerging as a crucial modulator of
myocardial function. This review will focus on the regulation of myocardial contraction
by peroxynitrite during health and disease, with a specific emphasis on cardiomyocyte
Ca2+ handling, proposed signaling pathways, and protein end-targets.
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The heart plays a vital role in the cardiovascular system by provid-
ing the specialized tissues and organs of the body with a continual
supply of oxygen and other essential nutrients. Modulation of
myocardial contraction allows the heart to meet the demands of
the body despite continual changes in metabolism. This modu-
lation occurs at several different levels, including the level of the
ventricular cardiomyocyte.
EXCITATION–CONTRACTION COUPLING
Cardiomyocyte contraction occurs via a process termed
excitation–contraction coupling, in which the electrical activity
of the heart is translated into cardiomyocyte contraction (Bers,
2001, 2002). This process commences with the cardiac action
potential and the depolarization of the myocyte membrane,
which leads to the opening of L-type Ca2+ channels (Bers, 2001,
2002). This causes an influx of Ca2+ into the myocyte via the
L-type Ca2+ current (ICa), and subsequently triggers the opening
of the sarcoplasmic reticulum (SR) Ca2+-release channels or
ryanodine receptors (RyRs). This results in an efflux of Ca2+
from the SR, which is the major Ca2+ store in the cardiomyocyte,
in a process termed Ca2+-induced Ca2+-release. This process
initiates the upstroke of the myocyte [Ca2+]i transient and this
Ca2+ is now available for myocyte contraction. SR Ca2+ load,
which represents the Ca2+ available for release from the SR, is
a critical determinant of [Ca2+]i transient amplitude and thus
myocyte contraction (Bassani et al., 1995; Trafford et al., 1995).
The [Ca2+]i transient is responsible for the activation of car-
diomyocyte contraction or shortening. When [Ca2+]i increases
within the cardiomyocyte, this Ca2+ diffuses to the myofilaments
and binds to troponin C (TnC) (Davis and Tikunova, 2008). This
induces a strong interaction between TnC and troponin I (TnI),
effectively destabilizing the interaction between TnI and actin.
This shifts the troponin–tropomyosin complex in such a way as
to allow the myosin head to bind directly to actin, thus leading to
the formation of a myosin crossbridge. Provided that ATP is read-
ily available to the myosin head, myocyte force production and/or
shortening ensues until Ca2+ is no longer bound to TnC.
Relaxation is initiated by the decline of the [Ca2+]i
transient, which is primarily mediated by the SR Ca2+-
ATPase/phospholamban complex (SERCA/PLB) and the
Na+/Ca2+ exchanger (NCX) (Bers, 2001, 2002). The SERCA/PLB
complex serves to re-sequester Ca2+ into the SR, while NCX
directly extrudes Ca2+ into the extracellular space. PLB is a
phosphoprotein that plays a critical role in the decline of the
[Ca2+]i transient by regulating the uptake of Ca2+ by SERCA.
Under basal conditions, PLB remains hypophosphorylated and
serves to inhibit the uptake of Ca2+ by SERCA. This inhibition
can be relieved upon PLB Serine16 phosphorylation by protein
kinase A (PKA), thus allowing greater uptake of Ca2+ into the
SR (Chu et al., 2000; Hagemann and Xiao, 2002; Mattiazzi et al.,
2006). There are two main serine/threonine protein phosphatases
that dephosphorylate PLB, protein phosphatase 1 (PP1) and
protein phosphatase 2a (PP2a) (Macdougall et al., 1991).
MODULATION OF EXCITATION–CONTRACTION COUPLING
Since every cardiomyocyte is recruited to contract with each
heartbeat, numerous endogenous systems have evolved to effec-
tively regulate the ventricular myocyte contractile state by modu-
lating excitation–contraction coupling. For example, stimulation
of the β-adrenergic receptor (β-AR) pathway results in positive
inotropic and lusitropic effects via modulation of key excitation–
contraction coupling proteins (Bers and Ziolo, 2001). Activation
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of the β-AR signaling pathway transpires with binding of an
agonist (e.g., epinephrine, isoproterenol) to the receptor, which
results in the dissociation of the Gsα subunit. Gsα induces cAMP
production via adenylate cyclase (AC). Increased cAMP then
activates the cAMP-dependent protein kinase or PKA, which
phosphorylates many different targets in the cardiomyocyte,
including ICa, RyR, TnI, and PLB. The end result is increased
Ca2+ influx, increased SR Ca2+ uptake, load, and release, and
decreased myofilament Ca2+ sensitivity. PLB phosphorylation at
Serine16 by PKA is one of the primary mechanisms responsible
for the observed positive inotropic and lusitropic effects of β-AR
stimulation (Chu et al., 2000; Li et al., 2000; Roof et al., 2011,
2012). Therefore, altering PLB phosphorylation levels will lead to
drastic changes in myocardial contraction and relaxation. Since
the β-AR pathway is perhaps the most important regulator of
myocardial contractility, this pathway itself is modulated by other
endogenous systems such as reactive nitrogen species (RNS).
REACTIVE NITROGEN SPECIES
RNS are quickly emerging as crucial modulators of myocar-
dial contraction during health and disease (Pacher et al., 2007).
Alterations in the production of these reactive species may be
responsible for part of the dysfunction that is observed during
many pathophysiological conditions of the myocardium and may
represent novel therapeutic targets. However, the modulation of
myocardial function by RNS is a relatively new field and many
questions remain unanswered. For example, studies have yet to
conclusively determine whether this dysfunction results from the
loss of endogenous RNS production [i.e., nitric oxide (NO)]
or from the production of supraphysiological levels of reactive
species. In all likelihood, this dysfunction stems from the par-
tial loss of localized RNS signaling coupled with an increase in
the production of more reactive species, including peroxynitrite.
Indeed, this appears to be the case (Feldman et al., 2008; Ziolo
et al., 2008).
NO is a well-known modulator of many physiological pro-
cesses, including neural transmission and the regulation of blood
pressure. However, NO is also surfacing as a key modulator
of myocardial function by serving as a regulator of excitation–
contraction coupling (Ziolo et al., 2001b, 2004; Wang et al.,
2008a,b, 2009, 2010) and β-AR signaling (Balligand et al., 1993;
Ziolo et al., 2001c). NO is produced endogenously within the
myocardium by three distinct isoforms of NO synthase (NOS)
(Ziolo and Bers, 2003). Neuronal NOS (NOS1) and endothelial
NOS (NOS3) are constitutively expressed within cardiomyocytes.
NOS1 and NOS3 produce low amounts of NO in phase with the
myocyte [Ca2+]i transient. Inducible NOS (NOS2), on the other
hand, is only expressed within cardiomyocytes during inflam-
matory responses which occur during many pathophysiological
conditions of the myocardium. NOS2 produces much higher
amounts of NO compared to constitutive isoforms and is [Ca2+]i
independent (Schulz et al., 1992; Ziolo et al., 1998, 2001a).
NO is known to signal through at least two distinct signal-
ing pathways: cGMP-dependent and cGMP-independent (Ziolo,
2008). cGMP-dependent signaling occurs through the activa-
tion of guanylate cyclase and protein kinase G (PKG), while
cGMP-independent signaling primarily occurs via direct protein
modification (e.g., S-nitrosylation) (Martinez-Ruiz and Lamas,
2004; Hess et al., 2005; Handy and Loscalzo, 2006; Kohr et al.,
2011b). NO has also been shown to directly activate AC indepen-
dent of β-AR activation, thus resulting in positive inotropic effects
via increased cAMP production and PKA activation (Vila-Petroff
et al., 1999). NO also signals by coupling to other reactive sig-
naling species (e.g., superoxide anion) to form related congeners,
such as peroxynitrite.
PEROXYNITRITE
Peroxynitrite (ONOO−) is a potent oxidant that is formed upon
the reaction of NO and superoxide. This reaction occurs with
an extremely high rate constant, making the formation of per-
oxynitrite quite favorable (Huie and Padmaja, 1993; Beckman
and Koppenol, 1996). Although peroxynitrite is a highly reac-
tive species, it is still capable of diffusing through biologi-
cal membranes and interacting with intracellular constituents
(Denicola et al., 1998). Under physiological conditions, perox-
ynitrite production remains low and potential oxidative damage
is reduced via endogenous cellular antioxidant defenses (Radi
et al., 2002a,b). Low levels of peroxynitrite may also serve to
modulate various intracellular signaling pathways. In fact, per-
oxynitrite appears to play a role in the regulation of many
important physiological processes. For example, peroxynitrite has
been demonstrated to modulate T cell proliferation (Brito et al.,
1999; Vig et al., 2004), platelet aggregation (Schildknecht et al.,
2008), and neutrophil adhesion (Zouki et al., 2001). Peroxynitrite
is thought to mediate these physiological processes by targeting
various proteins and/or signaling pathways, including receptor
tyrosine kinases, mitogen-activated protein kinases, phospho-
inositide 3-kinase/protein kinase B (Akt), protein kinase C, and
nuclear factor κB (Pacher et al., 2007).
The production of peroxynitrite increases greatly during the
pathogenesis of numerous disorders, such as cerebral ischemia-
reperfusion (Thiyagarajan et al., 2004; Dhar et al., 2006), myocar-
dial ischemia-reperfusion (Wang and Zweier, 1996; Cheung et al.,
2000), heart failure (Ferdinandy et al., 2000; Mihm et al., 2001;
Zhang et al., 2007), atherosclerosis (Buttery et al., 1996; Luoma
et al., 1998), diabetes (Suarez-Pinzon et al., 1997, 2001), and
septicemia (Bhattacharyya et al., 2004). Although peroxynitrite
production plays a critical role for neutrophils and macrophages
inmicrobial defense (Macmicking et al., 1997; Nathan and Shiloh,
2000), supraphysiological levels of peroxynitrite are almost always
detrimental to cellular function. Peroxynitrite exerts damaging
effects by altering protein structure and function via irreversible
nitration to tyrosine residues and cysteine oxidation (Kamat,
2006; Pacher et al., 2007). Peroxynitrite can also exert effects by
reacting with transition metal centers, including heme prosthetic
groups (Pietraforte et al., 2001; Lin et al., 2007) and zinc-thiolate
motifs (Crow et al., 1995; Zou et al., 2004), thus resulting in the
inactivation of many enzymes. NOS3, an enzyme which exerts
many cardioprotective effects (Janssens et al., 2004; Buys et al.,
2007; Wang et al., 2008b, 2012), can be inhibited upon exposure
to high levels of peroxynitrite (Zou et al., 2004; Chen et al., 2010).
Additionally, hydroxylation of ring systems (Szabo et al., 1997;
Tuo et al., 1998), DNA strand breakage (Szabo et al., 1996, 1997),
and lipid peroxidation (Radi et al., 1991a,b) can be induced by
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peroxynitrite. Apoptosis and necrosis can also be triggered upon
peroxynitrite exposure (Gilad et al., 1997; Arstall et al., 1999;
Pacher et al., 2002; Levrand et al., 2006). Moreover, peroxynitrite
will react with other molecules, such as carbon dioxide (CO2),
to form additional reactive species (i.e., nitrosoperoxycarbonate)
(Uppu and Pryor, 1996). Increased peroxynitrite production is
further compounded by the depletion of endogenous antioxidant
pools, including glutathione (GSH), which is amajor scavenger of
reactive oxygen and nitrogen species (Valko et al., 2007). The pro-
duction of peroxynitrite occurs endogenously in several different
ways.
Peroxynitrite can be formed endogenously within the ventric-
ular cardiomyocyte through various routes under physiological
and pathophysiological conditions. A major source for the pro-
duction of peroxynitrite includes the NOS isoforms (namely
NOS1 and NOS2) and via non-classical pathways (namely
nitroxyl).
NOS1 has been shown to co-immunoprecipitate with xan-
thine oxidoreductase (Khan et al., 2004), a superoxide producing
enzyme. This interaction between NOS1 and xanthine oxidore-
ductase will lead to the physiological production of low levels
of peroxynitrite. Additionally, NOS1 can potentially produce
both NO and superoxide (Pou et al., 1992; Xia et al., 1996),
although this is more likely to occur with NOS uncoupling dur-
ing various disease states (Sun et al., 2008). NOS uncoupling
will increase superoxide production by NOS1, while decreasing
NO production. NOS1 is considered to be a physiological regu-
lator of myocardial function by increasing basal contractility, the
force-frequency response, and the response to β-AR stimulation
(Barouch et al., 2002; Khan et al., 2003; Vandsburger et al., 2007;
Wang et al., 2008a, 2010).
NOS2 is a high output NOS isoform and can readily become
uncoupled upon depletion of the cofactors necessary for NO pro-
duction, thus leading to the production of both NO and super-
oxide (Xia and Zweier, 1997; Mungrue et al., 2002). Additionally,
NADPHoxidase and xanthine oxidoreductase can increase super-
oxide production under the same pathophysiological conditions
in which NOS2 is expressed (Heymes et al., 2003; Minhas et al.,
2006). This will lead to the production of supraphysiological lev-
els of peroxynitrite. NOS2 is considered to be a pathophysiologi-
cal regulator of myocardial function by decreasing the response to
β-AR stimulation (Drexler et al., 1998; Ziolo et al., 2001b, 2004).
In addition to the NO produced via NOS1 and NOS2, addi-
tional sources of peroxynitrite include nitroxyl, the one elec-
tron reduction production of NO (Kirsch and De Groot, 2002).
Endogenous production of nitroxyl within cardiomyocytes may
occur through various routes, including via hydrogen atom
extraction by NO (Akhtar et al., 1985). NOS1 also remains a
potential source for the production of nitroxyl (Schmidt et al.,
1996; Ishimura et al., 2005). Therefore, the reaction of nitroxyl
with O2 will lead to the production of low levels of peroxynitrite.
PEROXYNITRITE AND CARDIOMYOCYTE CONTRACTION
Recent work has now demonstrated that peroxynitrite is able
to modulate excitation–contraction coupling, and hence con-
tractility. In the myocardium, peroxynitrite has been demon-
strated to exert biphasic effects on cardiomyocyte contraction.
More specifically, low levels of peroxynitrite (which occurs under
physiological conditions) have been shown to produce positive
inotropic effects on cardiomyocyte function. Conversely, high
levels of peroxynitrite (which occurs under pathophysiological
conditions) are extremely detrimental to myocardial function by
decreasing cardiomyocyte contraction.
PHYSIOLOGICAL REGULATION OF CARDIOMYOCYTE
CONTRACTION BY PEROXYNITRITE
Many studies have shown that low levels of peroxynitrite induce
positive inotropic effects on basal myocardial function. Chesnais
et al. demonstrated peroxynitrite to increase force production
in frog atrial and ventricular fibers using authentic peroxyni-
trite, as well as the peroxynitrite donor SIN-1 (Chesnais et al.,
1999a,b). Paolocci et al. confirmed this positive effect on basal
function in mammalian ex vivo myocardial preparations using
SIN-1 (Paolocci et al., 2000). Interestingly, this effect was reversed
with GSH and occurred independently from global changes in
cAMP and cGMP levels. Furthermore, we demonstrated that
a low concentration of peroxynitrite increased basal and sub-
maximal β-AR-stimulated contraction in isolated cardiomyocytes
(Kohr et al., 2008a). We next investigated the molecular mecha-
nisms of this peroxynitrite-induced increase in basal contraction
and found that it was dependent upon PLB. That is, perox-
ynitrite had no effect on basal contraction in PLB knockout
myocytes. Further explorations demonstrated that peroxynitrite
resulted in the enhancement of PLB Serine16 (the PKA site)
phosphorylation (Kohr et al., 2010) and was abolished upon
inhibition of PKA with KT5720 (Kohr et al., 2010). Low per-
oxynitrite also increased PKA activity in cardiac homogenates
and in purified preparations of PKA containing both the reg-
ulatory and catalytic subunits of PKA, indicating that perox-
ynitrite induces a direct, cAMP-independent activation of PKA.
This direct effect may occur via S-nitrosylation, S-glutathiolation
and/or cysteine oxidation (Ferdinandy, 2006; Pacher et al., 2007),
as PKA has several cysteine residues which are susceptible to
these types of modifications (Brennan et al., 2006; Burgoyne and
Eaton, 2009; Kohr et al., 2011a). Thus, low levels of peroxyni-
trite shift the kinase/phosphatase balance leading to increased
PLB phosphorylation. Interestingly, the effect of low perox-
ynitrite on submaximal β-AR-stimulated contraction was still
observed in PLB knockout myocytes, suggesting another protein
target. A recent study demonstrated that PKA phosphorylation
of RyR contributes to the inotropic effect of β-AR stimulation
using a low dose of isoproterenol (Shan et al., 2010). Thus,
peroxynitrite-mediated activation of PKA may also lead to RyR
phosphorylation contributing to the contractile effects of β-AR
stimulation. Non PKA-mediated effects of peroxynitrite have
also been reported such as S-nitrosylation of SERCA2a, which
increases Ca2+ uptake and relaxation (Bencsik et al., 2008).
We previously demonstrated in healthy ventricular cardiomy-
ocytes that NOS1 signals partly through the production of per-
oxynitrite (Wang et al., 2008a). Additionally, we and others have
shown that NOS1 signaling increases myocardial contraction
(basal, force-frequency response and β-AR-stimulated contrac-
tion) (Barouch et al., 2002; Khan et al., 2004; Wang et al., 2008a),
parameters that can be considered physiologic. These effects are
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consistent with the positive inotropic effects of peroxynitrite (i.e.,
peroxynitrite increased basal and submaximal β-AR-stimulated
contraction). Interestingly, NOS1−/− myocytes exhibit reduced
basal contraction and a diminished response to β-AR stimula-
tion compared to wild type (Barouch et al., 2002; Khan et al.,
2004; Wang et al., 2008a), which we and others demonstrated to
occur in part through a reduction in RyR activity (Wang et al.,
2010) and PLB Serine16 phosphorylation (Wang et al., 2008a;
Zhang et al., 2008). This is also consistent with the PLB and
RyR dependent effects of low peroxynitrite (Kohr et al., 2008a).
In addition, NOS1 has been shown to potentially modulate PKA
activity, as PKA inhibition decreased PLB Serine16 phosphoryla-
tion and the rate of relaxation in wild-type myocytes, but had no
effect in NOS1−/− myocytes (Zhang et al., 2008). Therefore, the
physiological production of low levels of peroxynitrite may serve
to maintain and/or increase basal and β-AR-stimulated myocyte
contraction, in part, through a direct, cAMP-independent acti-
vation of PKA. Further, the loss of localized NOS1-mediated
peroxynitrite production under certain disease states where NOS1
translocates to the sarcolemma (Damy et al., 2003, 2004) may
result in decreased myocyte contraction similar to that observed
with the knockout of NOS1.
PATHOPHYSIOLOGICAL REGULATION OF CARDIOMYOCYTE
CONTRACTION BY PEROXYNITRITE
At high concentrations, peroxynitrite is detrimental to myocar-
dial function. Studies examining high levels of peroxynitrite
have demonstrated dysfunctional effects via direct exposure or
using peroxynitrite donors (Lopez et al., 1997; Ma et al., 1997;
Ferdinandy et al., 1999, 2000; Katori et al., 2006). Additionally,
we have demonstrated a NOS2-induced reduction in β-AR-
stimulated RyR activity through a cGMP-independent mech-
anism, likely via peroxynitrite (Ziolo et al., 2001b). Further,
we and others have shown a reduction in β-AR-stimulated
contraction upon exposure to a high concentration of SIN-1
in isolated cardiomyocytes (Stojanovic et al., 2001; Yin et al.,
2002). We demonstrated that this SIN-1-induced decrease in
β-AR-stimulated contraction occurred via peroxynitrite forma-
tion and was also dependent upon PLB. However, unlike low
peroxynitrite, high peroxynitrite results in a reduction in PKA-
dependent PLB Serine16 phosphorylation (Kohr et al., 2008b).
Upon further examination of this signaling pathway, we deter-
mined that high peroxynitrite increased phosphatase activity
in cardiac homogenates (low peroxynitrite had no effect on
phosphatase activity). Interestingly, it appears that peroxynitrite
selectively targets PP2a as we observed an increased interaction
between PLB and PP2a (but not PP1) with peroxynitrite (Kohr
et al., 2009). This reversible effect may occur through a pro-
tein intermediate or from the direct modification of PP2a by
peroxynitrite via S-nitrosylation, S-glutathiolation, and/or cys-
teine oxidation (Ferdinandy, 2006; Pacher et al., 2007). PP2a
has several cysteine residues which are susceptible to these types
of modifications (Sommer et al., 2002). Consistent with our
results, peroxynitrite has been shown to directly activate PP2a
via tyrosine nitration in endothelial cells (Wu and Wilson, 2009).
Thus, high levels of peroxynitrite shift the kinase/phosphatase
balance leading to decreased PLB phosphorylation. While PP2A
also modulates RyR phosphorylation (Terentyev et al., 2003),
we did not observe any effects of high peroxynitrite on
the β-AR response in PLB knockout myocytes, which sug-
gests that this may be a compartmentalized effect targeted
to PLB.
The production of high levels of peroxynitrite in the
myocardium is often associated with the expression of NOS2 (Xia
et al., 1998; Mungrue et al., 2002) and increased ROS produc-
tion via NADPH oxidase (Byrne et al., 2003; Heymes et al., 2003)
and xanthine oxidase (Tziomalos and Hare, 2009). Specifically
in heart failure, studies have shown an increase in peroxynitrite
production (Ferdinandy et al., 2000; Mihm et al., 2001; Zhang
et al., 2007), as well as a diminished response to β-AR stimula-
tion (Houser et al., 2000). We have previously demonstrated that
myocytes isolated from failing human hearts expressing NOS2,
displayed a blunted response to β-AR stimulation (Ziolo et al.,
2004). This dysfunction could be reversed upon acute inhibi-
tion of NOS2, such that peak [Ca2+]i and cell shortening were
significantly increased. This same functional phenomenon was
observed with high peroxynitrite (i.e., peroxynitrite decreased
contraction during β-AR stimulation). Interestingly, PP2a activ-
ity has been shown to be increased in heart failure (Boknik et al.,
2000), while PLB Serine16 phosphorylation has been shown to be
decreased (Bartel et al., 1996; Schwinger et al., 1999; Sande et al.,
2002). Therefore, the increased formation of peroxynitrite that
occurs in heart failure may be an important component of the
β-AR dysfunction observed in heart failure and other cardiomy-
opathies. A recent study demonstrated that peroxynitrite was an
independent risk predictor of post-operative complications (i.e.,
atrial fibrillation, need for inotropic support, length of hospital
stay) among patients undergoing cardiac surgery for various rea-
sons (Antoniades et al., 2012), further validating the significance
of increased peroxynitrite in cardiac dysfunction.
PEROXYNITRITE AND MITOCHONDRIAL FUNCTION
The processes of cardiomyocyte contraction and Ca2+ reup-
take/extrusion are dependent upon ATP. Through oxidative phos-
phorylation, mitochondria produce the majority of the ATP that
is necessary for these processes. Ca2+ is also taken up by the mito-
chondria during each Ca2+ transient, and this serves to couple
excitation–contraction coupling with energetic demand (Maack
and O’Rourke, 2007). Recent work has demonstrated that mito-
chondrial function is modulated by RNS (i.e., NO, peroxynitrite).
NO is a well-established physiological mediator of mitochon-
drial respiration, and these effects primarily result from the
inhibition of Complex I and IV of the electron transport chain
(Brookes, 2004). Although Complex I and IV are similarly inhib-
ited by NO, this inhibition occurs through two distinct mecha-
nisms. In the case of Complex I, NO acts via S-nitrosylation of
the 75 kDa subunit of Complex I (Burwell et al., 2006). Complex
IV, on the other hand, is inhibited through the reaction of NO
with the catalytic metals located in the active site of cytochrome
c oxidase (Cleeter et al., 1994; Palacios-Callender et al., 2004).
NO can also target additional mitochondrial proteins by reacting
with superoxide to yield peroxynitrite. The effects of peroxynitrite
on mitochondrial function are much less defined when com-
pared to those of NO, but peroxynitrite has the potential to
signal physiologically in the mitochondria or to contribute to
mitochondrial dysfunction during pathological states.
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Peroxynitrite has been shown to target many different pro-
teins in the mitochondria and this can occur via S-nitrosylation,
as reported to occur with Complex I of the electron transport
chain (Borutaite et al., 2000), or through irreversible nitration
and/or cysteine oxidation. The reversibility of S-nitrosylation may
represent a potential physiological signaling pathway for per-
oxynitrite in the mitochondria, while the effects of irreversible
nitration and cysteine oxidation are likely to be highly detrimen-
tal to mitochondrial function. For example, peroxynitrite induced
the irreversible inhibition of mitochondrial creatine kinase, and
this effect could not be reversed with GSH treatment (Konorev
et al., 1998). Peroxynitrite was also shown to inactivate the Kreb’s
cycle enzyme aconitase (Castro et al., 1994). Additional mito-
chondrial targets of peroxynitrite include the adenine nucleotide
translocase (Vieira et al., 2001), nicotinamide nucleotide tran-
shydrogenase (Forsmark-Andree et al., 1996), and Complex I, II,
and V of the electron transport chain (Radi et al., 1994; Cassina
and Radi, 1996; Riobo et al., 2001). Manganese superoxide dis-
mutase, which is a major enzyme for the decomposition of
superoxide in the mitochondria, is another target of peroxyni-
trite and is inactivated via nitration (Quijano et al., 2001). This
peroxynitrite-induced inactivation is further compounded by
increased levels of superoxide, which could in turn lead to the
formation of additional peroxynitrite. Hence, a decrease in energy
supply by inhibiting mitochondrial function could contribute to
the depressed contractile function associated with high levels of
peroxynitrite.
LOW vs. HIGH LEVELS OF PEROXYNITRITE
Peroxynitrite has a biphasic effect on cardiomyocyte contrac-
tion, which is mainly concentration dependent (low vs. high).
However, since peroxynitrite is highly reactive and rapidly decom-
posed, accurate measurements of concentration are difficult. In
addition, determining intracellular concentrations of peroxyni-
trite with exogenously applied authentic peroxynitrite or the
peroxynitrite donor SIN-1 is challenging, making direct com-
parisons to endogenously produced peroxynitrite formidable.
In general, concentrations of 30μM or less of authentic per-
oxynitrite or 100μM or less of SIN-1 will result in positive
inotropic effects as described. We have previously reported that
10μM SIN-1 produces 3 nM/min peroxynitrite in our physio-
logical saline solution (Kohr et al., 2008a). Higher concentra-
tions (100μM authentic peroxynitrite or 200μM SIN-1) will
result in negative inotropic effects as described. We have pre-
viously reported that 200μM SIN-1 results in a 6X greater
production of peroxynitrite compared to 10μM SIN-1 (Kohr
et al., 2008b). We consider these levels to be physiologically
and pathophysiologically relevant as we and others observed
similar effects on function in studies investigating NOS1 and
NOS2 signaling. Thus, these concentrations of peroxynitrite
result in the activation of various signaling pathways (PKA, PP2A,
S-nitrosylation, etc.) resulting in the enhancement or reduction
of myocardial contractility. There have been exceptions reported
in which low concentrations of authentic peroxynitrite/SIN-
1 resulted in negative inotropic effects or high concentra-
tions of SIN-1 resulted in positive inotropic effects (Yin et al.,
2002; Katori et al., 2006; Kohr et al., 2008a). Thus, other fac-
tors also contribute to the contractile effects of peroxynitrite
such as cardiomyocyte contractile state, signaling pathway acti-
vation (e.g., S-nitrosylation, nitration, cGMP or cAMP) as
well as the length of exposure (Schulz et al., 1997; Ziolo,
2008).
FIGURE 1 | Physiological signaling pathway of low peroxynitrite. This is a diagrammatic representation of low peroxynitrite signaling and various proposed
end targets within the cardiomyocyte. The endogenous production of low peroxynitrite can occur via NOS1/xanthine oxidase.
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FIGURE 2 | Pathophysiological signaling pathway of high peroxynitrite. This is a diagrammatic representation of high peroxynitrite signaling and various
proposed end targets within the cardiomyocyte. The endogenous production of high levels of peroxynitrite can occur via NOS2/NADPH oxidase/xanthine
oxidase.
Studies have also been performed using very high concentra-
tions of authentic peroxynitrite (mM) or long exposure times.
These studies revealed irreversible effects of peroxynitrite that
depressed myocyte contraction and inactivated SERCA (Ishida
et al., 1996; Knyushko et al., 2005; Lokuta et al., 2005). A con-
sequence of this very high concentration of peroxynitrite is likely
a toxic effect that results in cell damage. For example, peroxyni-
trite is able to activate matrix metalloproteinases that will result
in the cleavage of α-actinin and TnI (Wang et al., 2002; Rork
et al., 2006; Sung et al., 2007; Leon et al., 2008). We believe that
very high concentrations of peroxynitrite can be produced in cer-
tain disease states such as heart failure or ischemia/reperfusion
injury which have reported SERCA inactivation via nitration or
TnI cleavage.
In conclusion, peroxynitrite is emerging as a crucialmodulator
of myocardial function during health and disease. Under phys-
iological conditions, low levels of peroxynitrite serve to main-
tain and/or increase basal and β-AR-stimulated contraction in
the myocardium. This occurs via RyR and PLB phosphoryla-
tion through direct PKA activation and SERCA activation via
S-nitrosylation (Figure 1). Conversely, supraphysiological levels
of peroxynitrite (due to NOS2 expression and increased ROS
levels via NADPH oxidase and xanthine oxidase) are detri-
mental to myocardial function and decrease β-AR-stimulated
cardiomyocyte contraction. This occurs via PLB dephosphoryla-
tion through PP2a activation, decreased RyR activity, mitochon-
drial dysfunction, and myofilament protein cleavage (Figure 2).
This dual effect lends critical insight into the physiological
and pathophysiological regulation of myocardial contraction by
peroxynitrite.
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